IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies	Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence	Recruiting	Phase 1	2026-06-01		NCT07309900

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shanghai IASO Biotechnology Co., Ltd	5
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	319

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	77

Clinical trials